2.38
-0.18(-7.03%)
Currency In USD
| Previous Close | 2.56 |
| Open | 2.55 |
| Day High | 2.62 |
| Day Low | 2.35 |
| 52-Week High | 8.83 |
| 52-Week Low | 1.96 |
| Volume | 2.47M |
| Average Volume | 2.15M |
| Market Cap | 271.07M |
| PE | -1.49 |
| EPS | -1.6 |
| Moving Average 50 Days | 2.81 |
| Moving Average 200 Days | 4.24 |
| Change | -0.18 |
If you invested $1000 in Fate Therapeutics, Inc. (FATE) 10 years ago, it would be worth $660.33 as of December 05, 2024 at a share price of $2.43. Whereas If you bought $1000 worth of Fate Therapeutics, Inc. (FATE) shares 5 years ago, it would be worth $179.07 as of December 05, 2024 at a share price of $2.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fate Therapeutics Announces Leadership Transition
GlobeNewswire Inc.
Nov 29, 2024 6:05 PM GMT
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate The
Fate Therapeutics to Present at Upcoming December Investor Conferences
GlobeNewswire Inc.
Nov 26, 2024 9:01 PM GMT
SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
GlobeNewswire Inc.
Nov 18, 2024 1:05 PM GMT
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with Fludarabine-free Conditioning an